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Resistance to retinopathy 
development in obese, diabetic and 
hypertensive ZSF1 rats: an exciting 
model to identify protective genes
Vincenza Caolo  1, Quentin Roblain2,3, Julie Lecomte3, Paolo Carai1, Linsey Peters2, 
Ilona Cuijpers1,2, Emma Louise Robinson  2, Kasper Derks4, Jurgen Sergeys  5, Agnès Noël3, 
Elizabeth A. V. Jones1, Lieve Moons  5 & Stephane Heymans1,2,6
Diabetic retinopathy (DR) is one of the major complications of diabetes, which eventually leads to 
blindness. Up to date, no animal model has yet shown all the co-morbidities often observed in DR 
patients. Here, we investigated whether obese 42 weeks old ZSF1 rat, which spontaneously develops 
diabetes, hypertension and obesity, would be a suitable model to study DR. Although arteriolar 
tortuosity increased in retinas from obese as compared to lean (hypertensive only) ZSF1 rats, vascular 
density pericyte coverage, microglia number, vascular morphology and retinal thickness were not 
affected by diabetes. These results show that, despite high glucose levels, obese ZSF1 rats did not 
develop DR. Such observations prompted us to investigate whether the expression of genes, possibly 
able to contain DR development, was affected. Accordingly, mRNA sequencing analysis showed that 
genes (i.e. Npy and crystallins), known to have a protective role, were upregulated in retinas from obese 
ZSF1 rats. Lack of retina damage, despite obesity, hypertension and diabetes, makes the 42 weeks 
of age ZSF1 rats a suitable animal model to identify genes with a protective function in DR. Further 
characterisation of the identified genes and downstream pathways could provide more therapeutic 
targets for the treat DR.
Globally, prevalence of diabetes has nearly doubled from 4.7% in 1980 to 8.5% of the adult population in 20141. 
Diabetes can lead to several complications affecting the cardiovascular system, kidneys, nerves, and eyes2. 
Diabetic retinopathy (DR) is one of the most serious complications of diabetes. Prolonged exposure to high blood 
glucose levels (hyperglycemia) results in severe damage of the retinal vasculature2–4. This can lead to blurred 
vision, dark spots, flashing lights, and eventually total loss of vision. DR is the leading cause of blindness5 and 
makes a big contribution to the total 11.6% of annual health-care costs accounted for diabetes6.
Currently, several animal models are being used to study the progression of DR, for example the strepto-
zotocin (STZ)-induced and Akimba mouse models (reviewed in3). All these models, however, present serious 
limitations and they do not reflect all stages of DR progression in humans. In addition, these models do not 
develop diabetes spontaneously, but are either chemically or genetically induced. For instance, STZ is a toxic 
substance that is injected in mice or rats to destroy the pancreatic β-cells3,7. The Akimba mouse develops DR 
due to the presence of the human Vascular Endothelial Growth Factor isoform 165 (hVEGF165) transgene, which 
induces an overexpression of VEGF in photoreceptors8. Among the few established animal models that develop 
diabetes spontaneously, the Zucker Diabetic Fatty (ZDF) rat represents an established model for type 2 diabetes. 
1Department of Cardiovascular Sciences, Centre for Molecular and Vascular Biology, KU Leuven, Belgium. 
2Department of Cardiology, CARIM School for Cardiovascular Diseases Faculty of Health, Medicine and Life 
Sciences, Maastricht University, Maastricht, The Netherlands. 3Laboratory of Tumor and Development Biology, 
GIGA-Cancer, University of Liège, Liège, Belgium. 4Department of Genetics and Cell Biology, CARIM School for 
Cardiovascular Diseases Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The 
Netherlands. 5Laboratory of Neural Circuit Development and Regeneration, Animal Physiology and Neurobiology 
Section, Department of Biology, KU Leuven, Leuven, Belgium. 6The Netherlands Heart Institute, Nl-HI, Utrecht, 
The Netherlands. Correspondence and requests for materials should be addressed to V.C. (email: Vincenza.caolo@
kuleuven.be)
Received: 27 March 2018
Accepted: 17 July 2018
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIENTIFIC REPORTS |  (2018) 8:11922  | DOI:10.1038/s41598-018-29812-w
However, ZDF rats did not show any clear sign of DR, i.e. vascular occlusion or regression9. Besides the ZDF, the 
obese ZDF/Spontaneously Hypertensive Heart Failure (SHHF) F1 hybrid (ZSF1) rat, which are the result of a 
cross between a ZDF female and a SHHF male, develops metabolic complications typical of type-2 diabetes and 
have a more severe phenotype than the ZDF parental strain. Both obese and lean control ZSF1 rats are hyperten-
sive10. However, the obese ZSF1 rats are also affected by diabetic nephropathy (DN), insulin resistance, obesity, 
hyperinsulinemia, hypercholesterolemia, congestive heart failure, and hypertriglyceridemia11. The ZSF1 rat is 
currently used as a model to study DN, whereas no scientific study on DR performed in these animals has been 
reported to date. In this study, we extensively investigated whether the ZSF1 rat could represent a suitable animal 
model to study the pathogenesis of DR. In order to assess the retinal vascular changes caused by diabetes, such as 
arteriolar tortuosity, obese and lean control ZSF1 rats were subjected to Heidelberg Retina Angiography (HRA) 
and additional histological analysis over a period of 42 weeks. We further examined the potential combined effect 
of chronic diabetes, obesity and hypertension on vasculature of retinas isolated from 6 and 42 weeks old obese 
and lean control ZSF1 rats, by assessing vascular density, pericyte coverage and number of microglia on whole 
mounted retina. The thickness of the neural retinal layers was assessed by Optical Coherence Tomography (OCT) 
over a period of 35 weeks. However, no differences were detected between obese and lean ZSF1 rats.
Despite the increase in vascular tortuosity, obese ZSF1 rats did not develop DR. The absence of a DR phe-
notype would suggest the existence of a protective gene expression profile in these rats. Consistently, deep 
sequencing analysis of mRNA isolated from retinas of 6 and 42 weeks old obese and lean ZSF1 rats, revealed the 
upregulation of several genes with a potential protective function, i.e. Neuropeptide Y (Npy) and several crystal-
lin genes, at 42 weeks. Whereas genes, previously described to drive vascular inflammation, such as Intercellular 
Adhesion Molecule 1 (Icam1) and Toll-like receptor 4 (Tlr4) were downregulated in retinas from obese rats 42 
weeks of age.
A deeper understanding on the role of Npy and the crystallin genes in the retina following stressful conditions 
such as diabetes could be beneficial for developing better tools to improve the condition of patients affected by DR 
and other diabetes related ocular complications.
Results
Arteriolar tortuosity is increased in obese ZSF1 rats over time. In the clinic, arteriolar tortuosity is 
routinely used as a marker to predict pathological neovascularization and rapid DR progression12. Therefore we 
assessed arteriolar tortuosity index in lean and obese ZSF1 rats over a period of 6 to 42 weeks of age. As shown in 
Fig. 1, the tortuosity index significantly increased in obese rats compared to their lean controls at 18, 26, 34 and 
42 weeks, but did not differ when comparing lean and obese ZSF1 rats at 5 and 14 weeks of age. Increase in weight 
and blood glucose levels was confirmed in obese ZSF1 rats at 18, 22 and 42 weeks as reported in Supplementary 
Figure 2A,B.
Retinal vascular density and pericyte coverage are not affected by diabetes or age. Besides 
vessel tortuosity, two characteristics of DR are pericyte dropout and pathological neovascularization. Specifically, 
pericyte dropout leads to capillary occlusions followed by hypoxia13,14. In the initial phase, blood vessels retract 
due to vessel instability caused by the loss of pericytes15. This leads to hypoxic areas, which in turn increases the 
expression of HIF-1 and subsequent VEGFA, resulting in pathological neovascularisation16,17. Remarkably, deep 
and superficial vascular density and pericyte coverage did not differ between lean and obese animals at 6 and 42 
weeks of age, but also there was no time-induced difference in obese and lean control ZSF1 rats at 42 weeks com-
pared to those at 6 weeks (Fig. 2B,C). These results suggest that the vascular density and pericyte coverage are not 
affected by both, age and diabetes in ZSF1 rats.
The number of microglia is affected by age, but not by diabetes. The activation of several signal-
ling pathways during DR results in increased inflammation4. Microglia constitute the resident immune cells of 
the central nervous system18 and they seem to play an important role during DR progression19–21. The number 
of Iba1-stained microglia was significantly higher in the retinas of both lean and obese ZSF1 rats at 42 weeks as 
Figure 1. Arterial tortuosity index of the retinal vasculature from lean and obese ZSF1 rats, between 5 and 42 
weeks old. Tortuosity index of the retinal arteries was increased in obese as compared to lean ZSF1 rat retinas 
of 18, 26, 34 and 42 weeks of age. No difference in arteriolar tortuosity was detected in rats of 5 and 14 weeks of 
age. All values are mean ± SD, **P < 0.01; ***P < 0.001; ****P < 0.0001.
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compared to lean and obese ZSF1 rat at 6 weeks (Fig. 3A,B), which is in line with an age-dependent increase21. 
However, the number of microglia did not differ between lean and obese ZSF1 either at 6 and 42 weeks of age 
(Fig. 3B), indicating that diabetes did not impact the microglia cell number in obese ZSF1 rat retinas.
The morphology of the vasculature is affected by age, but not by diabetes. Next, we determined 
whether obese ZSF1 rats showed any changes in the morphology of their retinal vascular network, stained with 
IB4, as compared to their lean controls. An illustration of junctions, segments, loops and branches is reported 
in Supplementary Figure 2. In the deep retinal vascular plexus, the number of junctions, segments, loops and 
branches were significantly decreased in 42 weeks old lean and obese rats as compared to the 6 weeks old lean 
and obese ZSF1 rats, respectively (Fig. 4A–D; Deep). Also, in the superficial vascular plexus, the number of 
junctions, segments and branches were significantly decreased in the 42 weeks old obese ZSF1 rats compared 6 
weeks old obese ZSF1 rats (Fig. 4A,B,D; Superficial). No significant difference was found in the number of loops 
in the superficial plexus between the groups (Fig. 4C; Superficial). Finally, no significant difference was found in 
the number of junctions, segments, branches and loops in the superficial and deep plexus of retinal vasculature 
between lean and obese ZSF1 rats at 6 and 42 weeks respectively. Overall, these results indicate that the vascular 
morphology in the retina is affected by age, but not by diabetes in both deep and superficial plexus. Functional 
Figure 2. Vascular density and pericyte coverage of retinal vasculature from 6 and 42 weeks old lean and obese 
ZSF1 rats. (A) IB4 (green), NG2 (red) and a merge signal of both the deep and superficial retinal vascular 
plexus. Scale = 50 µm. (B) Quantification of vascular density of the deep and superficial plexus shown in 
percentage of IB4 signal of the total area (n = 6–7 per data point). (C) Quantification of pericyte coverage of the 
deep and superficial plexus shown as ratio of the NG2 and IB4 positive areas (n = 5–7 per data point). All values 
are mean ± SD.
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analysis, i.e. OCT scan, of the retina was also performed. As shown in Supplementary Figure 3, no differences in 
neural retina were found between obese and lean rats.
Upregulation of Npy and several crystallin genes in retinas from obese ZSF1 rats of 42 weeks of 
age. To identify genes able to prevent the onset of DR in obese ZSF1 rat, we performed sequencing of mRNA 
of retinas from 6 and 42 weeks old lean and obese, ZSF1 rats. Principal Component Analysis (PCA) resulted in a 
clear separation of lean from obese ZSF1 rats (Fig. 5). Although less pronounced, a separation based on age could 
be also distinguished within the lean and obese groups, i.e. 6 versus 42 weeks old lean and 6 versus 42 weeks old 
obese ZSF1 rats (Fig. 5).
We performed statistical analysis on all genes expressed between the different groups. A gene was considered 
to be expressed when at least 5 reads were found aligned in at least all samples of one of the groups. In Fig. 6, we 
report the differential expressed genes (DEGs) found for all the comparisons. Changes in the expression of a total 
of 911 protein coding genes were identified (FC >1.5 False Discovery Rate (FDR) < 0.05). A large majority of 
the DEGs identified per comparison was unique to that specific comparison, i.e. the DEGs were not significantly 
regulated in the other comparisons. Ingenuity Pathway Analysis (IPA) analysis showed the differently regulated 
pathways within the 4 comparisons: lean vs obese 6 weeks old, lean vs obese 42 weeks old, lean 6 vs lean 42 weeks 
old, obese 6 vs obese 42 weeks old (Supplementary table 1–4). Noteworthy, the leptin signalling pathway appeared 
to be differently regulated in the obese 6 and obese 42 weeks old (Supplementary table 4), confirming the meta-
bolic phenotype affecting old obese ZSF1 rats (Supplements, table 4).
Among genes only upregulated in the retinas from 42 weeks old ZSF1, we found Versican (Vcan), 
Forkhead Box D1 (Foxd1), MHC Class I Polypeptide-Related Sequence B (Micb) and Npy, whereas Cxadrl1, 
as Immunoglobulin Superfamily Member 11 (IGSF11), and Mal-like (Mall) were downregulated (Fig. 7). 
Remarkably, among the top regulated genes in retina from 6 vs 42 weeks old obese ZSF1, were several members 
of the crystallin gene family (Fig. 8). Among them, Crybb3, Cryba2, Crygc, Crygb, Crygf, Crybb2, Cryba1, Cryba4, 
Crygs, were upregulated in obese 42 as compared to obese 6 weeks old. However, Crybb3, Cryba2, Crygc, Crygb, 
Crygf, Cryba1 were only upregulated in obese 42, indicating that their expression was likely affected by diabetes 
and metabolic diseases. On the other hand, Icam1 and Trl4, both known to play a determinant role during vascu-
lar inflammation, were both downregulated in retinas from obese rat 42 weeks old (Fig. 9).
Discussion
The ZSF1 rat, despite being obese, hypertensive, diabetic and hyperlipidemic, did not present any clear vascular 
defects in their retinas that could be attributed to progressive DR. Although vascular tortuosity increased in the 
diabetic rats over time, vascular density and pericyte coverage did not differ between diabetic and non-diabetic 
rats of 6 and 42 weeks of age. Microglia number and vascular network morphology differed in aged rats, but were 
unaffected by diabetes. Thickness of neural retina layers were also assessed by OCT scan, however no differences 
Figure 3. Number of microglia located in the retinas from 6 and 42 weeks old lean and obese ZSF1 rats. (A) IB4 
(green) and Iba1 (cyan) and merge signal of the deep retinal vascular plexus. Scale = 50 µm. (B) Quantification 
of microglia number counted in the intermediate and deep vascular plexus (n = 5–7 per data point). All values 
are mean ± SD, ****P < 0.0001.
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were found at the different analysed time points, in lean and obese rats. Absence of damage in the retinas from 
diabetic aged ZSF1 rats offered us the existing opportunity to investigate on possible molecular mechanisms 
that would prevent these animals from developing DR. We, therefore, performed mRNA sequencing in order to 
identify genes differentially expressed in retina isolated from lean and obese ZSF1 rats 6 and 42 weeks of age with 
a possible protective role against DR.
The RNA sequencing revealed that 85 genes were upregulated in the retinas from 42 weeks old when com-
pared to their lean control ZSF1 rats. Among the regulated genes, we found genes known to play a role in angi-
ogenesis, inflammation, cellular stress and death. We found that genes involved in the process of angiogenesis, 
Figure 4. Quantification of vascular network morphology of the vascular deep and superficial plexus of 
retinas from 6 and 42 weeks old lean and obese ZSF1 rat. Number of junctions (A), segments (B), loops (C) 
and branches (D) in the deep and superficial retinal vascular plexus (n = 5–7 per data point). All values are 
mean ± SD, *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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i.e. VCAN and Foxd1, were upregulated. In addition, the expression of the Micb gene, whose increase has been 
associated with degeneration of retinal ganglionic cells (RGC) and development of glaucoma22, was upregulated 
in retinas from 42 weeks old ZSF1 rats. On the other hand, Cxadrl1, important for excitatory synaptic localiza-
tion and plasticity, and Mall, encoding a component of raft mediated trafficking in endothelial cells, were both 
downregulated. Although changes in expression of the above mentioned genes, together with increased vascular 
tortuosity, would suggest that an initial vascular and neuronal damage of the retinas in ZSF1 rats 42 weeks of age 
is occurring, we also found that several genes with a potential protective function, i.e. Npy and several crystallin 
genes, were significantly upregulated in retinas from 42 weeks old ZSF1 rats. Conversely, genes involved in vascu-
lar inflammation, like Icam1 and Trl423,24, were downregulated in in retinas from 42 weeks old ZSF1 rats.
Npy was first isolated in 1982 and is highly conserved between species25. In the retina, Npy seems to be 
required during development being expressed in different cell types26. Specifically, the neuroprotective role of Npy 
against excitotoxicity has been largely documented27–29. As such, Npy was shown to reduce the [Ca2+]i increase in 
rat neurons preventing their death30. The activation of several Npy receptors has been reported to protect retinal 
cells from necrosis or glutamate induced cell death31. Npy and its receptors are expressed in retinal endothelial 
cells, likely playing a role in retinal related vascular diseases30. In support of this, few studies have shown that 
Leucine to Proline polymorphism in the Npy gene was related to an increased predisposition to develop diabetic 
retinopathy in type 2 diabetic patients32–34. However, results on the role of Npy in oxygen-induced retinopathy 
model have been controversial. Whereas two studies33,35 suggested a positive role for Npy in the progression of 
neovascularization during DR, Schmid and collaborators36 reported a decreased expression level of Npy in a sim-
ilar model. Therefore, further research is still needed to clarify the exact contribution of Npy in retinal vascular 
diseases.
Several crystalline genes were also found to be upregulated in retinas of obese ZSF1 when compared to lean 42 
weeks of age. The crystallin genes were first described to encode structural proteins of the lens37, but they are also 
expressed in other tissues and organs such as the retina38, heart39 and skeletal muscle40. The crystallins are divided 
in two families: the α-crystallin belonging to the small heat shock proteins (sHSP) and the β- and γ-crystallins 
Figure 5. Principal component analysis (PCA) plot based on the first two (PC1–PC2) components of mRNA 
from retinas from 6 and 42 weeks old lean and obese ZSF rats.
Figure 6. Venn diagram showing overlap between the differentially expressed genes (DEG) found in different 
comparisons, i.e. by age (Lean 6 vs Lean 42, purple and Obese 6 vs Obese 42, gray) and diabetes and metabolic 
syndrome (Lean 6 vs Obese 6, green and Lean 42 vs Lean 42, blue). The cut-offs for the DEGs were set to a Fold 
Change < or > 1,5 and (FDR) < 0.05. The numbers in the circle depict the number of DEGs found for that 
specific condition: i.e. in the bottom circle 51 DEGs are found in both Lean 6 vs Lean 42 and Lean 42 vs Obese 42.
www.nature.com/scientificreports/
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forming the β/γ superfamily. Besides their function in lens transparency and reflex index, the α-crystallins are 
induced in response to stress and injury, displaying molecular chaperone and anti-apoptotic activity41. The β/γ 
crystallins regulate vascular remodelling during eye development and RCG axon regeneration42. Crystallin gene 
Figure 7. Heat map displaying fold changes of the differential expressed genes. The colors are ranging from red 
(−1 <= log2 Fold Change (FC)) to orange (FC ~ 0) to green (FC >= 1).
Figure 8. Heat map displaying fold changes of the differential expressed crystallin (Crys) genes. The colors are 
ranging from blue (−2 <= log2 Fold Change (FC)) to green (FC ~ 0) to yellow (FC >= 2).
www.nature.com/scientificreports/
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expression is altered upon DR38, but their exact function during this process remains controversial. Although 
few studies have suggested a protective role of αB-crystallin genes against pathological neovascularization of the 
retina during diabetes, one study reported that delivery by intravitreous injection of recombinant adenovirus 
expressing αA-crystallin prevented vascular leakage and decreased pericyte loss in STZ-induced mouse model 
of diabetes43–46. The majority of those studies, however, investigated the role of α-crystallin genes during DR, 
whereas little is still known on the role of β/γ crystallins. From our RNA sequencing analysis, it emerges that dia-
betes and the metabolic syndrome induce the expression of crystallin β (i.e. Crybb3, Cryba2, Cryba1) and γ (i.e. 
Crygc, Crygb, Crygf) in the retina, whereas we did not observe any significant effect on α crystallins.
Noteworthy, β and γ crystallin genes are upregulated in the retina of Nuc1 mutant rats as compared to wild 
type littermates47. Nuc1 mutants are characterized by a spontaneous mutation that affects neuronal and vascular 
remodelling and retinal function48. In particular, astrocytes at the vascular front seem to express β and γ crys-
tallins together with VEGF. Moreover, in human persistent fetal vasculature (PFV) disease, in which the hyaloid 
vasculature does not regress normally, astrocytes expressed β and γ crystallins47, suggesting a role for those crys-
tallins in vascular stabilization in the eye. Besides being vasculoprotective, β/γ crystallins may also modulate axon 
regeneration49. Β/γ crystallins induce ciliary neurotrophic factor (CNTF) and brain derived neurotrophic factor 
(BDNF) both in vitro and in vivo49. In particular Crybb2 is secreted by cultured retinas during axon regeneration, 
and induces axon elongation in cultured RCG axons42. In conclusion, β/γ crystallin genes, which are upregulated 
in the retinas of 42 weeks old obese ZSF1 rats, might play a role in vascular stabilization and neuronal survival, 
preventing ZSF1 rats from developing DR.
Vascular inflammation and leukostasis are early events in diabetic retinopathy with serious functional con-
sequences. During DR leukocytes adhere to endothelial cells, causing vascular occlusion, macrophage accu-
mulation and vascular tissue damage50. Several are the genes involved in these processes. Among them, Tumor 
Necrosis Factor α (Tnfα) modulates endothelial cell permeability and adhesion molecule expression51. Also, the 
expression of CD11a, CD11b, and CD18 integrins was shown to be increased on the surface of neutrophils from 
diabetic rats50. Proteins such as, Tnfα, NF-kB are Trl4 have been extensively shown to regulate the inflammatory 
response23. Finally Icam1 inhibition was reported to prevent diabetic retinal leukostastis and blood-retinal bar-
rier breakdown24. Therefore, we assessed the expression of all these vascular inflammation markers and to our 
surprise we found that Icam1 and Trl4 were downregulated in in retinas from 42 weeks old ZSF1 rats, likely con-
tributing to the protective mechanisms by reducing leukostasis and inflammation.
Although the diabetic, hypertensive, obese and hyperlipidemic ZSF1 rat does not develop overt DR, it rep-
resent a useful model to identify new molecular signalling pathways beneficial to prevent the onset of DR. 
Remarkably, RNA sequencing analysis led us to identify Npy, β/γ crystalline, Icam1 and Trl4 genes that are differ-
ently expressed in lean and obese ZSF1 rats and could play a role in protecting old obese ZSF1 rats from develop-
ing DR. The roles that Npy and β/γ crystallins play in vascular remodelling and axon regeneration, and that Icam1 
and Trl4 play in vascular inflammation, make them interesting candidates for new studies to target a complex 
ocular disease such as DR. Further characterization of the molecular mechanisms regulated by β/γ crystallins and 
Npy, Icam1 and Trl4, whose activation might be protective against DR, could possibly help us to design novel and 
more effective therapeutic strategies to improve the clinical outcome of patients affected by DR.
Methods
Animals. All animal procedures conformed to the relevant guidelines and regulations of, and were approved 
by, the Animal Welfare Committee of the KU Leuven University. Male obese ZSF1 rats (ZSF1-LeprfaLeprcp/Crl) 
(Charles River Inc.) were used in this study. Male lean, non-diabetic, non-obese, but hypertensive ZSF1 rats 
were used as control. Rats were sacrificed at 6 and 42 weeks of age. The weight of each overnight fasting rat was 
recorded. Diabetes was confirmed after blood collection from rat tails at different time points (18, 22 and 42 
weeks) and glucose levels were determined with an automated glucose analyzer device (Glucometer, Menarini 
Diagnostics).
Figure 9. Heat map displaying fold changes for genes indicated. The colors are ranging from white (−1 <= 
log2 Fold Change (FC)) to light blue (FC = ~ 0) to dark blue/violet (FC >= 1).
www.nature.com/scientificreports/
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Heidelberg Retinal Angiography. Rats were anesthetized by intraperitoneal injection of ketamine 
(Ketalar, 10 mg/mL) at a dose of 6.0 mg/kg and medetomidine hydrochloride (Domitor, 1.0 mg/mL) at a dose of 
0.4 mg/kg. Rats were injected intraperitoneally with 1 mL fluorescein sodium salt (Sigma, F6377-100G) 10% solu-
tion in saline. After the experiment, rats were awaken by intraperitoneal injection of atipamezole hydrochloride 
(Antisedan, 5 mg/ml) at a dose of 0.5 mg/kg. Images were taken using a Heidelberg Retina Angiograph 2 (HRA2) 
(Heidelberg Engineering GmbH) according to the manufacturer’s recommendations. Tortuosity index was cal-
culated from these photographs using the ImageJ software as previously described52.
Retina Isolation and Immunofluorescence. Retina isolation and staining were carried out as previ-
ously described53. Blood vessels were stained with 20 µg/mL Isolectin GS-IB4 (IB4) (I21411, Thermo Fisher). 
Pericytes were stained with 5 µg/mL primary antibody Mouse anti-NG2 (Cat. No. NG2 37-2700 Invitrogen) and 
microglia were stained with 2 µg/mL primary polyclonal antibody Rabbit anti-Iba1 (019_19741, Wako Laboratory 
Chemicals). 1:100 Goat anti-Mouse Alexa 568 (A11031, Molecular Probes) and 1:100 Donkey anti-Rabbit Alexa 
647 (A31573, Invitrogen) were used as secondary antibodies. Photos were taken using a Leica DFC350 FX digital 
camera or Leica TCS SPE confocal.
The images were processed and analyzed in ImageJ. The superficial and deep vascular plexus were separated 
based on the IB4 images. All analyses were performed on 20X magnification images with ImageJ Angiogenesis 
Analyzer. This tool allows detailed quantification of several vasculature structures, such as number of junctions, 
segments, loops and branches as shown in Supplementary Figure 2. Junctions were defined as meeting points 
of segments and/or branches. Segments were described as elements between two junctions and branches are 
elements between a junction and extremity. Loops were defined as areas enclosed by segments54. The percentage 
of IB4 positive areas was evaluated to determine vascular density. The percentage of NG2 positive areas was 
measured and the ratio of IB4 and NG2 positive areas was calculated to determine pericyte coverage. For area 
calculations, the images were quantified by ImageJ Area Fraction analysis. Microglia were quantified by ImageJ 
Cell Counter analysis.
Optical Coherence Tomography. To assess thickness of the retinal layers and retinal morphology, a 
spectral domain optical coherence tomography (SD-OCT) system (Envisu R2210, Bioptigen, Morrisville, NC, 
USA) was used. To evaluate retinal morphology and neural retinal thickness an InVivoVue Diver 2.2 software 
(Bioptigen) was used as previously described in55.
RNA isolation and integrity. RNA was isolated from the ZSF1 retinas using the mirVana™ miRNA 
Isolation Kit (Cat. No 1560, Ambion) according to the mirVana™ miRNA Isolation kit protocol. In a 20 µL reac-
tion volume, 1 µg RNA per sample was reverse transcribed into cDNA via the miScript II RT Kit (Cat. No. 218160, 
Qiagen), according to the manufacturer’s instructions using the 5x miScript HiFlex Buffer.
The integrity of the RNA from each sample was scored on the Agilent 2100 Bioanalyzer (Agilent) by using an 
Expert Eukaryote Total RNA Pico chip according manufacturer’s protocol. Samples that had an RNA Integrity 
Number (RIN) value of over 6 were subsequently used for mRNA sequence library generation.
mRNA sequencing library generation. The mRNA sequencing library was generated using TruSeq 
mRNA sample preparation kit (Illumina) according to manufacturer’s protocol. In short, mRNA was enriched 
using magnetic beads coated with poly-dT, followed by fragmentation. The fragmented mRNA- enriched sam-
ples were subjected to cDNA synthesis by reverse transcriptase, followed by dA-tailing and ligation of specific 
double-stranded bar-coded adapters. Subsequently, a 15 cycles library amplification was performed and after 
clean-up, the sizes of the libraries were determined on an Agilent 2100 Bioanalyzer (Agilent) via an DNA 1000 
chip according manufacturer’s protocol. Pooled libraries consisting of equal molar samples were sequenced on a 
high-output 75 bp single read on the NextSeq500 (Illumina).
Total RNA analysis pipeline. The analyses of sequencing datasets were performed as earlier described56. 
In short, reads were aligned to the rat rn6 reference genome using TopHat43 and exonic reads were summed per 
transcript and transcripts were referred to as being expressed when at least five aligned reads were present in all 
samples of at least one of the groups.
Pathway analysis. The differentially transcribed genes for the obese, i.e. 6 and 42 weeks, or lean, i.e. 6 and 
42 weeks, ZSF1 rats were investigated for over-represented pathways. We used normalized count reads, i.e. counts 
per million and log2 transformed, and performed a pathway enrichment analysis with Ingenuity pathway analysis 
(IPA) software.
Statistics. Statistical analysis was performed by using GraphPad Prism 6. Statistical differences were exam-
ined by applying one and two-way analysis of variance tests (ANOVAs) followed by Tukey’s Multiple Comparison 
Test. A p value of less than 0.05 (P < 0.05) was considered statistically significant. Data are presented as the 
mean ± standard deviation (SD) or ± standard error of the mean (SEM) of 5–7 retinas per group.
Data availability. All data generated or analysed during this study are included in this published article (and 
its Supplementary Information files).
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